Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.
 BACK TO LIST

Laboratory Report

Patient
Name: Roberts, Carly
DOB: 10-DEC-1969 (Age: 56)
Gender: female
Address:
2 Price meadow
LE4 Mitchellborough (United Kingdom)
ID: 9384-259853-9 (ECI)
Report
Date: 28-APR-2023
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
St Matthews Health & Community Centre
Malabar Road 62-66
LE1 4 Leicester (United Kingdom)
Specimen
Collected: 28-APR-2023

Hematology

Test 28-APR-2023 Reference Range Unit
Leukocytes [#/volume] in Blood by Automated count 9.3 4.0 - 11.0 10*3/uL
Erythrocytes [#/volume] in Blood by Automated count 5.0 4.2 - 5.4 10*6/uL
Hemoglobin [Mass/volume] in Blood 15.9 12 - 16 g/dL
Hematocrit [Volume Fraction] of Blood by Automated count 39.6 36 - 46 %
MCV [Entitic mean volume] in Red Blood Cells by Automated count 83.2 80 - 100 fL
MCH [Entitic mass] by Automated count 27.8 27 - 33 pg
MCHC [Entitic Mass/volume] in Red Blood Cells by Automated count 34.6 32 - 36 g/dL
Erythrocyte [DistWidth] in Blood by Automated count 12.4 11.5 - 14.5 %
Platelets [#/volume] in Blood by Automated count 301.1 150 - 450 10*3/uL

Chemistry

Test 28-APR-2023 Reference Range Unit
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 937.6 H 0 - 450 pg/mL
Glucose [Mass/volume] in Serum or Plasma 78.6 65 - 99 mg/dL
Urea nitrogen [Mass/volume] in Serum or Plasma 7.9 7 - 20 mg/dL
Creatinine [Mass/volume] in Serum or Plasma 0.7 0.5 - 1.1 mg/dL
Calcium [Mass/volume] in Serum or Plasma 9.4 8.6 - 10.3 mg/dL
Sodium [Moles/volume] in Serum or Plasma 141.1 135 - 145 mmol/L
Potassium [Moles/volume] in Serum or Plasma 4.2 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Serum or Plasma 101.0 98 - 110 mmol/L
Carbon dioxide, total [Moles/volume] in Serum or Plasma 28.9 22 - 32 mmol/L
Protein [Mass/volume] in Serum or Plasma 7.2 6.6 - 8.3 g/dL
Albumin [Mass/volume] in Serum or Plasma 4.6 3.5 - 5.2 g/dL
Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 0.1 - 1.2 mg/dL
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 61.6 32 - 91 U/L
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21.5 7 - 56 U/L
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 13.5 10 - 40 U/L
Magnesium [Mass/volume] in Serum or Plasma 2.1 1.7 - 2.2 mg/dL
Cholesterol [Mass/volume] in Serum or Plasma 151.0 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 114.5 0 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 101.4 H 0 - 100 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 26.7 L 40 - 60 mg/dL
Hemoglobin A1c/Hemoglobin.total in Blood 5.4 4.0 - 5.6 %
Troponin I.cardiac [Mass/volume] in Serum or Plasma by High sensitivity method 0.0 0.0 - 19.9 pg/mL
Ferritin [Mass/volume] in Serum or Plasma 127.3 13 - 150 ug/L
Iron [Mass/volume] in Serum or Plasma 73.1 50 - 170 ug/dL
Iron binding capacity [Mass/volume] in Serum or Plasma 348.2 250 - 450 ug/dL
Iron saturation [Mass Fraction] in Serum or Plasma 30.8 15 - 50 %

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
Laboratory results are largely within normal limits except for elevated NT-proBNP, mildly increased LDL cholesterol, and low HDL cholesterol. The elevated NT-proBNP may indicate possible cardiac dysfunction or heart failure and warrants clinical correlation. Lipid profile suggests increased cardiovascular risk. No evidence of anemia, infection, renal, or hepatic dysfunction. Recommend further cardiac evaluation and lipid management as clinically indicated.